Continued Long Term Responses to Ibrutinib plus Venetoclax Treatment for Relapsed/Refractory CLL in the Blood Cancer UK TAP Clarity Trial

被引：0
|
作者：
Hillmen, Peter
Boucher, Rebecca H.
Webster, Nichola
Dalal, Surita
Brock, Kristian
Yates, Francesca
Sankhalpara, Chhaya
Macdonald, Donald
Fegan, Christopher
McCaig, Alison
Schuh, Anna
Pettitt, Andrew
Gribben, John G.
Patten, Piers
Devereux, Stephen
Bloor, Adrian
Fox, Christopher P.
Forconi, Francesco
Rawstron, Andrew
Hillmen, Peter
机构：
来源：
BLOOD | 2020年 / 136卷
关键词：
D O I：
10.1182/blood-2020-136960
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study
    Hillmen, Peter
    Rawstron, Andy
    Brock, Kristian
    Vicente, Samuel Munoz
    Yates, Francesca
    Bishop, Rebecca
    Macdonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers E. M.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Munir, Talha
    BLOOD, 2018, 132
  • [2] Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: Results of the Bloodwise TAP Clarity Study
    Munir, T.
    Rawstron, A.
    Brock, K.
    Vicente, S. Munoz
    Yates, F.
    Bishop, R.
    Macdonald, D.
    Fegan, C.
    McCaig, A.
    Schuh, A.
    Pettitt, A.
    Gribben, J. G.
    Patten, P. E.
    Devereux, S.
    Bloor, A.
    Fox, C. P.
    Forconi, F.
    Hillmen, P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 185 : 25 - 25
  • [3] Ibrutinib plus venetoclax in Relapsed/Refractory CLL: The CLARITY Study
    Munir, Talha
    Rawstron, Andrew
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca
    Bishop, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John
    Patten, Piers
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher
    Forconi, Francesco
    Hillmen, Peter
    LEUKEMIA & LYMPHOMA, 2020, 61 : 227 - 228
  • [4] Ibrutinib Plus Venetoclax in Relapsed/Refractory CLL: The CLARITY Study
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 20 - 21
  • [5] Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study
    Hillmen, Peter
    Rawstron, Andy C.
    Brock, Kristian
    Munoz-Vicente, Samuel
    Yates, Francesca J.
    Bishop, Rebecca
    Boucher, Rebecca
    MacDonald, Donald
    Fegan, Christopher
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Patten, Piers E. M.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    Munir, Talha
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (30) : 2722 - +
  • [6] THE INITIAL REPORT OF THE BLOODWISE TAP CLARITY STUDY COMBINING IBRUTINIB AND VENETOCLAX IN RELAPSED, REFRACTORY CLL SHOWS ACCEPTABLE SAFETY AND PROMISING EARLY INDICATIONS OF EFFICACY
    Hillmen, P.
    Rawstron, A.
    Munir, T.
    Brock, K.
    Vincente, S. Munoz
    Jefferson, Y.
    Paterson, K.
    Fox, C. P.
    Gribben, J.
    Bloor, A.
    Schuh, A.
    Forconi, F.
    HAEMATOLOGICA, 2017, 102 : 311 - 311
  • [7] The initial report of the bloodwise tap clarity study combining ibrutinib and venetoclax in relapsed, refractory CLL shows acceptable safety and promising early indications of efficacy
    Munoz-Vicente, Samuel
    Bishop, Rebecca
    Hillmen, Peter
    Munir, Talha
    Rawstron, Andy
    Brock, Kristian
    Fox, Christopher
    Gribben, John
    Bloor, Adrian
    Jefferson, Yolande
    Schuh, Anna
    Forconi, Francesco
    LEUKEMIA & LYMPHOMA, 2017, 58 : 239 - 239
  • [8] Initial Results of Ibrutinib Plus Venetoclax in Relapsed, Refractory CLL (Bloodwise TAP CLARITY Study): High Rates of Overall Response, Complete Remission and MRD Eradication after 6 Months of Combination Therapy
    Hillmen, Peter
    Munir, Talha
    Rawstron, Andy
    Brock, Kristian
    Vicente, Samuel Munoz
    Yates, Francesca
    Bishop, Rebecca
    Fegan, Christopher
    Macdonald, Donald
    McCaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John G.
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher P.
    Forconi, Francesco
    BLOOD, 2017, 130
  • [9] Initial results of ibrutinib plus venetoclax in relapsed, refractory CLL (Bloodwise TAP CLARITY Study): high rates of overall response, complete remission and MRD eradication after 6 months of combination therapy
    Munir, Talha
    Rawstron, Andrew
    Brock, Kristian
    Vicente, Samuel Munoz
    Yates, Francesca
    Bishop, Rebecca
    Fegan, Christopher
    Macdonald, Donald
    Mccaig, Alison
    Schuh, Anna
    Pettitt, Andrew
    Gribben, John
    Devereux, Stephen
    Bloor, Adrian
    Fox, Christopher
    Forconi, Francesco
    Hillmen, Peter
    BRITISH JOURNAL OF HAEMATOLOGY, 2018, 181 : 34 - 35
  • [10] Combined Venetoclax and Ibrutinib for Patients with Previously Untreated High-Risk CLL, and Relapsed/Refractory CLL: A Phase II Trial
    Jain, Nitin
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Burger, Jan A.
    Borthakur, Gautam
    Takahashi, Koichi
    Bose, Prithviraj
    Estrov, Zeev
    Jabbour, Elias J.
    Konopleva, Marina
    Alvarado, Yesid
    Kadia, Tapan
    Yilmaz, Musa
    DiNardo, Courtney D.
    Ohanian, Maro
    Cortes, Jorge E.
    Kanagal-Shamanna, Rashmi
    Patel, Keyur
    Garg, Naveen
    Wang, Xuemei
    Fru, Nina
    Cruz, Nichole
    Gandhi, Varsha
    Plunkett, William
    Kantarjian, Hagop M.
    Keating, Michael J.
    Wierda, William G.
    BLOOD, 2017, 130
12345